[go: up one dir, main page]

AR011509A1 - Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna. - Google Patents

Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.

Info

Publication number
AR011509A1
AR011509A1 ARP970105177A ARP970105177A AR011509A1 AR 011509 A1 AR011509 A1 AR 011509A1 AR P970105177 A ARP970105177 A AR P970105177A AR P970105177 A ARP970105177 A AR P970105177A AR 011509 A1 AR011509 A1 AR 011509A1
Authority
AR
Argentina
Prior art keywords
vaccine
diphtheria
tetane
pertusis
reinforcer
Prior art date
Application number
ARP970105177A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR011509A1 publication Critical patent/AR011509A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una vacuna contra la difteria, el tétanos y la tos ferina, que comprende una baja dosis de cada uno de los siguientes: toxoide (D), toxoide tetánico (D)toxoide de la tos ferina (PT), emaglutinina filamentosa (FHA) hipertactina (69K). Lavacun a mantiene una capacidad para prevenir la tos ferina al mismotiempo que muestra una reactogenicidad excepcionalmente baja, también se proporcionan vacunas de combinacion que comprenden antígenos adicionales.
ARP970105177A 1996-11-07 1997-11-06 Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna. AR011509A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition

Publications (1)

Publication Number Publication Date
AR011509A1 true AR011509A1 (es) 2000-08-30

Family

ID=10802615

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105177A AR011509A1 (es) 1996-11-07 1997-11-06 Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.

Country Status (30)

Country Link
EP (2) EP1240905B3 (es)
JP (1) JP3980652B2 (es)
KR (1) KR100518044B1 (es)
CN (1) CN1130226C (es)
AR (1) AR011509A1 (es)
AT (2) ATE295178T1 (es)
AU (1) AU710475B2 (es)
BR (2) BR9712917A (es)
CA (1) CA2271008C (es)
CO (1) CO4910171A1 (es)
CY (2) CY2407B1 (es)
CZ (1) CZ295954B6 (es)
DE (3) DE69733285T3 (es)
DK (2) DK0941117T3 (es)
ES (2) ES2182131T3 (es)
GB (1) GB9623233D0 (es)
HK (1) HK1050473B (es)
HU (1) HU224126B1 (es)
IL (1) IL129530A (es)
LU (1) LU91183I2 (es)
NO (2) NO320186B1 (es)
NZ (1) NZ335384A (es)
PL (1) PL188460B1 (es)
PT (2) PT941117E (es)
SA (1) SA98181128B1 (es)
SI (2) SI1240905T1 (es)
TR (1) TR199900979T2 (es)
TW (1) TW471971B (es)
WO (1) WO1998019702A1 (es)
ZA (1) ZA979984B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
KR102236498B1 (ko) 2013-03-08 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 무세포 백일해 백신
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
ATE105858T1 (de) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
EP0835663B1 (en) 1992-05-23 2009-09-30 GlaxoSmithKline Biologicals S.A. Combined vaccines comprising Hepatitis B surface antigen and other antigens

Also Published As

Publication number Publication date
SI0941117T1 (en) 2002-12-31
BR9712917A (pt) 1999-12-07
SI1240905T1 (en) 2005-10-31
HU224126B1 (hu) 2005-05-30
AU710475B2 (en) 1999-09-23
NO992156L (no) 1999-05-04
EP0941117B1 (en) 2002-08-28
DK0941117T3 (da) 2002-11-18
KR100518044B1 (ko) 2005-09-30
GB9623233D0 (en) 1997-01-08
PT1240905E (pt) 2005-09-30
DE69733285D1 (de) 2005-06-16
HK1022638A1 (en) 2000-08-18
SA98181128B1 (ar) 2006-03-25
EP1240905B3 (en) 2009-08-26
CY2407B1 (en) 2004-09-10
NO992156D0 (no) 1999-05-04
KR20000053092A (ko) 2000-08-25
ES2182131T3 (es) 2003-03-01
HUP9904287A3 (en) 2001-05-28
TW471971B (en) 2002-01-11
BRPI9712917B1 (pt) 2019-12-03
CZ295954B6 (cs) 2005-12-14
LU91183I2 (fr) 2005-09-20
EP1240905A1 (en) 2002-09-18
ES2240647T3 (es) 2005-10-16
HK1050473B (en) 2006-03-03
BRPI9712917B8 (pt) 2021-05-25
HUP9904287A1 (hu) 2000-04-28
NZ335384A (en) 2000-10-27
JP2001503422A (ja) 2001-03-13
EP0941117A1 (en) 1999-09-15
DK1240905T3 (da) 2005-07-18
ATE295178T1 (de) 2005-05-15
AU5319698A (en) 1998-05-29
CZ164099A3 (cs) 1999-10-13
CA2271008A1 (en) 1998-05-14
TR199900979T2 (xx) 1999-07-21
CO4910171A1 (es) 2000-04-24
HK1050473A1 (en) 2003-06-27
DE122005000046I1 (de) 2005-12-29
DE69715031D1 (de) 2002-10-02
NO2006005I1 (no) 2006-05-08
PT941117E (pt) 2002-12-31
ES2240647T7 (es) 2010-03-31
ATE222773T1 (de) 2002-09-15
DE69733285T3 (de) 2010-03-25
ZA979984B (en) 1998-07-23
EP1240905B1 (en) 2005-05-11
DE69733285T2 (de) 2006-01-12
CN1236321A (zh) 1999-11-24
NO320186B1 (no) 2005-11-07
DE69715031T2 (de) 2003-05-08
CY2568B1 (en) 2008-07-02
PL333127A1 (en) 1999-11-22
NO2006005I2 (no) 2010-04-12
CA2271008C (en) 2008-07-22
JP3980652B2 (ja) 2007-09-26
DK1240905T5 (da) 2010-01-11
WO1998019702A1 (en) 1998-05-14
PL188460B1 (pl) 2005-02-28
IL129530A0 (en) 2000-02-29
CN1130226C (zh) 2003-12-10
IL129530A (en) 2005-11-20

Similar Documents

Publication Publication Date Title
AR011509A1 (es) Composicion de vacuna que comprende antigenos de difteria, tetano y tos ferina(pertusis) acelular y su uso para la manufactura de un medicamento util como reforzador de vacuna.
Lawrence et al. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
UY26801A1 (es) Composición de vacuna
NO20015073D0 (no) Vaksiner
AR025750A1 (es) Vacunas
DK1276896T3 (da) Epitop-synkronisering i antigen-præsenterende celler
BR9106748A (pt) Vacina de hyopneumomiae micoplasma inativado e metodo de seu uso
ES2597832T3 (es) Vacuna acelular contra la tosferina
CY1114864T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοαοενισχυτικο εκδοχο σαπωνινης
DE69527202D1 (de) Proteinartige adjuvantien
MX9709870A (es) Uso de esporocistos u occistos para preparar una vacuna contra coccidiosis.
LU91591I2 (fr) Combinaison d'antoxine diphtérique, d'anatoxine tétanique,d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type1, type 2 et type 3 (Triaxis Polio)
DK1725258T3 (da) Kombinationsvacciner med lav dosis Hib-konjugat
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
ATE419873T1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
PT1024824E (pt) Composicao de vacina dispersivel solida para administracao oral
CO2025007834A2 (es) Composiciones inmunogénicas y métodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
DK365287A (da) Fremgangsmaade til dyrkning af bordetella pertussis, pertussis toxoid, pertussis vacciner og fremgangsmaade til fremstilling af pertussis vacciner
DE60042243D1 (de) Mukosale dtpa impfstoffe
AR023536A1 (es) Vacunas
AR131340A1 (es) Composiciones inmunogénicas y métodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile
Cohen et al. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes

Legal Events

Date Code Title Description
FG Grant, registration